Avian Paramyxovirus 9

Overview, Taxonomy, and Genomic Architecture of Avian Paramyxovirus 9

Avian Paramyxovirus 9 (APMV-9) is one of several serotypes within the genus Avulavirus, a member of the family Paramyxoviridae. Although it has received considerably less research attention compared to the extensively studied Newcastle disease virus (APMV-1), APMV-9 displays unique biological characteristics that underscore its importance in avian epidemiology and vaccine research. As an avian pathogen, APMV-9 is of interest not only because of its role in natural reservoirs but also for its potential use as a vector in vaccine development and its implications for avian health management, as highlighted by global organizations such as the CDC, WHO, WOAH, and FAO.

Taxonomy

APMV-9 belongs to a diverse group of viruses classified under the genus Avulavirus. According to established taxonomic schemes, avian paramyxoviruses are assigned to distinct serotypes based on serological homology and genetic analysis. APMV-9 is antigenically and genetically discrete from the more pathogenic APMV-1, and its evolutionary divergence is marked by unique variations in its protein-coding sequences and genome regulatory elements [1]. Although only a few studies have specifically characterized APMV-9, its placement within the avulavirus group is supported by comparative analyses that examine the gene order and conserved motifs present in its genome. Such analyses typically reveal a conserved arrangement of six structural protein-encoding genes that have been identified in all known avulaviruses, reinforcing both its evolutionary lineage and its taxonomic status within the Paramyxoviridae family.

The antigenic differences between APMV-9 and other serotypes, such as APMV-1 and APMV-3, have been confirmed through serological assays and experimental challenge studies in avian species [2]. These differences are crucial not only for accurate diagnosis and surveillance but also for understanding the evolutionary pressures that drive antigenic drift among avian paramyxoviruses. Consequently, while APMV-9 is not known to cause the economically devastating outbreaks associated with more virulent strains like APMV-1, its circulation among avian populations provides important insights into viral evolution, host specificity, and the dynamics of virus-host interactions.

Genomic Architecture

The genomic organization of APMV-9 mirrors the canonical gene order observed in other members of the Avulavirus genus. Its non-segmented, single-stranded, negative-sense RNA genome is organized in the order 3′-N-P-M-F-HN-L-5′, where the six major proteins are encoded sequentially. The nucleoprotein (N) encapsidates the viral RNA, while the phosphoprotein (P) and the large polymerase protein (L) form the core components of the RNA-dependent RNA polymerase complex critical for viral transcription and replication. The matrix protein (M) plays a central role in virus assembly and budding, and the fusion (F) and hemagglutinin-neuraminidase (HN) glycoproteins are integral to viral entry and spread within the host [1].

Although comprehensive whole-genome sequencing studies specifically focusing on APMV-9 remain limited, its genome length is presumed to be comparable to that of other serotypes in the genus, approximately 15 kilobases. Within this framework, both the leader and trailer regions, which flank the coding sequences, are highly conserved and are known to contain regulatory signals essential for replication. These non-coding regions, along with the intergenic junctions between gene sequences, contribute to a transcriptional gradient that ultimately influences viral protein expression levels. Variations, even subtle, in these regulatory domains can impact replication efficiency and pathogenicity. For instance, studies evaluating the replication of various APMV serotypes in animal models have suggested that differences in the fusion protein cleavage motif could be a determinant of virulence, a factor that appears to influence the attenuated replication of APMV-9 in certain hosts [3, 2].

The HN protein, which is involved in receptor binding and neuraminidase activity, is of particular interest when comparing genomic architectures because its sequence divergence often reflects adaptations to specific avian hosts. In the case of APMV-9, variations in the HN gene may result in altered fusion activation thresholds and receptor specificity compared with its more virulent counterparts. Although detailed mutational analyses specific to APMV-9’s HN and F proteins are scarce, existing literature suggests that these proteins likely retain the conserved domains necessary for function yet may possess unique amino acid substitutions that contribute to its overall attenuated phenotype.

Advances in reverse genetics techniques, which have been successfully applied to other avulaviruses [3], hold significant promise for further elucidating the molecular determinants underlying APMV-9’s replication and immunogenicity. Such systems enable researchers to systematically manipulate genomic elements, ranging from the coding sequences of structural proteins to the regulatory motifs in non-coding regions, and assess the subsequent effects on viral behavior in vitro and in relevant animal models. The outcome of these studies is expected to deepen our understanding of how the genomic architecture of APMV-9 influences its pathogenic profile and its capacity for inducing host immune responses.

Biological and Epidemiological Considerations

From an epidemiological perspective, APMV-9 has been shown to induce virus-specific serum antibodies in experimental animal models, such as rhesus macaques and chickens, indicating that it is capable of establishing infection even though its replication is relatively restricted compared to other serotypes [3, 2]. In chickens, experimental infection with APMV-9 has been associated with a partial induction of neutralizing antibodies that can cross-react with more pathogenic isolates of APMV-1, suggesting that prior exposure to APMV-9 may alter the host’s susceptibility to other avian paramyxoviruses. Although APMV-9 has not been recognized as a major cause of disease outbreaks in commercial poultry, its presence in wild bird populations and its potential to serve as a natural vaccine vector offer important avenues for future research, particularly in the context of strategies recommended by global animal health authorities.

The interplay between APMV-9’s taxonomic identity, its conserved genomic structure, and its observed immunogenic properties underlines a delicate balance that defines its role within avian ecosystems. Its limited pathogenicity in both avian and non-avian hosts, along with its ability to induce measurable immune responses, makes it a candidate for further evaluation as a live attenuated

Molecular Pathogenesis and Host-Virus Interactions of Avian Paramyxovirus 9

The molecular pathogenesis of Avian Paramyxovirus 9 (APMV-9) is emerging as an area of particular interest in the ongoing study of avian paramyxoviruses, given the unique interplay between its genetic determinants and the host’s immune responses. As with other members of the Avulavirus genus, APMV-9 exhibits a negative-sense, single-stranded RNA genome encoding a set of conserved proteins that govern viral attachment, fusion, replication, and immune modulation. Although most of the extensive research to date has been focused on APMV serotype 1 or Newcastle disease virus (NDV), comparative analyses among serotypes indicate that APMV-9 possesses several distinguishing molecular features that underpin its pathogenesis and the nature of its interaction with avian hosts [2, 4].

At the heart of its infectious cycle lies the fusion (F) protein, whose cleavage site has been widely documented to serve as a critical determinant of virulence and tissue tropism among avian paramyxoviruses. For APMV-9, the F protein is typically characterized by a cleavage site motif that includes a single basic amino acid residue, a feature that is consistent with an avirulent or low pathogenic phenotype [2, 4]. This restriction in the number of basic residues limits the breadth of proteases capable of processing the precursor fusion glycoprotein (F_0) into its active subunits (F_1 and F_2), thereby reducing the possibility of systemic viral spread. In practical terms, the limited proteolytic activation of APMV-9 in host tissues confines replication to specific cell types, predominantly within the respiratory tract, where the repertoire of host proteases is most favorable for viral entry and propagation. This molecular constraint not only attenuates the virulence of the virus but also defines its host interaction pattern, with replication kinetics being modulated by the availability and activity of specific cellular enzymes [4].

APMV-9’s hemagglutinin-neuraminidase (HN) surface glycoprotein plays a dual role in receptor recognition and in facilitating viral release following replication. The HN protein binds to sialic acid-containing receptors on the surface of target cells, initiating the process of viral entry via endocytosis. Furthermore, the receptor-destroying activities of the neuraminidase domain aid in preventing virion aggregation and facilitate the liberation of newly formed virus particles. Despite the lower pathogenicity often associated with APMV-9, subtle differences in the receptor binding domain of HN, compared to more pathogenic serotypes, might influence host cell specificity and immune recognition. These variations contribute to its distinct host-virus interaction profile, often eliciting a more moderate immune response that can still be sufficient to restrict further viral dissemination while priming the host immune system for pathogen recognition [2, 4].

Once inside the host cell, the viral RNA-dependent RNA polymerase complex, comprised primarily of the large (L) protein and assisted by the phosphoprotein (P), orchestrates transcription and replication of the viral genome. The fidelity and efficiency of this polymerase complex are crucial for the maintenance of the quasispecies diversity within infected hosts, which in turn can influence the dynamics of host adaptation. For APMV-9, limited studies suggest that while the virus maintains a relatively conserved genomic organization, subtle allelic variations may arise during replication, particularly in genes encoding the F and HN proteins. These variations can be selectively advantageous in different host environments, such as in chickens versus waterfowl, and can lead to differential outcomes in the pattern of viral spread and immune system engagement [4]. Importantly, although APMV-9 is considered to have a low pathogenic profile in experimental settings, its ability to modulate gene expression and to possibly adapt rapidly through mutations under selective pressure remains an area requiring continuous investigation.

Host innate immune responses play a central role in countering APMV-9 infection. Engagement of pattern recognition receptors (PRRs) such as retinoic acid-inducible gene I (RIG-I) and other cytoplasmic sensors triggers antiviral signaling cascades, leading to the production of type I interferons and pro-inflammatory cytokines. In the case of APMV-9, the containment of the infection is likely aided by the timely activation of these innate immune pathways, which limit viral replication and spread. However, as with some other APMV serotypes, there is evidence that the virus may possess mechanisms to dampen or evade certain aspects of host antiviral responses. For instance, viral proteins can interfere with interferon regulatory factor (IRF) signaling or block the activities of downstream effectors, although the extent of immune evasion by APMV-9 appears less pronounced than in highly virulent NDV strains [4]. This delicate balance allows the virus to replicate sufficiently to sustain its transmission cycle in natural hosts, particularly among wild birds, while avoiding the severe immunopathology associated with more aggressive infections.

The interplay between APMV-9 and its host is not solely defined by the virus’s capacity to initiate infection; it also extends to secondary effects such as cross-protection against other avian paramyxoviruses. Notably, experimental immunization studies have demonstrated that prior infection with APMV-9 can influence subsequent immune responses to more virulent strains of APMV-1. In these instances, the generation of neutralizing antibodies, albeit at modest levels, serves as a protective marker and may limit the systemic spread of virulent NDV upon challenge [2]. This phenomenon underscores the potential for pathogenic interference, which may be leveraged in vaccine strategies that seek to elicit heterologous protection through controlled exposure to less virulent serotypes.

Epidemiologically, while surveillance data is more robust for serotypes such as APMV-1, the presence of APMV-9 in wild bird populations has been increasingly documented in regions with active avian health monitoring programs. International organizations including the CDC, WHO, and WOAH emphasize the importance of monitoring even the less pathogenic avian viruses because of their potential to serve as reservoirs for genetic exchange and emergence of new strains. APMV-9, therefore, occupies a critical niche in the overall landscape of avian paramyxoviruses, acting as both an immune modulator and a potential source of genetic diversity that might, under the right conditions, contribute genetic material to more virulent viruses through recombination or reassortment events [2, 4].

Understanding the molecular pathogenesis and host interactions of APMV-9 not only deepens our insight into the biology of avian paramyxoviruses but also informs strategies for surveillance, vaccine development, and ecological management. With its intrinsically lower virulence yet distinctive molecular attributes, APMV-9 exemplifies the complex equilibrium between viral replication strategies and host immune defenses that defines many avian pathogens, a balance that is critical for designing effective intervention methods in both commercial poultry and wild bird settings, as advocated by international health authorities such as the FAO and WOAH.

Epidemiology and Transmission Dynamics in Avian Populations

The epidemiology of avian paramyxoviruses, including serotype 9 (APMV-9), is defined by complex interactions among wild and domestic avian hosts, environmental factors, and biological mechanisms that drive viral evolution. Although APMV-9 remains less extensively characterized compared with the prototypical APMV-1 (Newcastle disease virus), research evaluating serotypes 2–9 has revealed distinct epidemiologic patterns and transmission dynamics that underscore the potential for widespread circulation and interspecies exchange in both free‐living and agricultural settings [2, 4]. Natural reservoirs in wild birds, particularly waterfowl and migratory species, facilitate viral persistence and dispersal over vast geographic regions, a dynamic that is critical in understanding outbreaks that affect economically sensitive poultry industries and trigger surveillance activities by global organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO).

Wild Bird Reservoirs and Migratory Flyways

Wild waterfowl and other migratory birds play a fundamental role in the maintenance and dissemination of APMV-9, as evidenced by surveillance studies that have documented a high prevalence of avian paramyxoviruses, including low-pathogenic strains, in these populations [5, 6]. Although most studies target APMV-1, the broad host range observed among wild birds extends to serotypes such as APMV-9, which circulate asymptomatically and rarely trigger overt disease. Molecular epidemiologic investigations have demonstrated that many avian paramyxoviruses exhibit high genetic diversity and maintain region-specific lineages, indicating that migratory routes act both as transmission corridors and as filters that limit intercontinental viral exchange [7]. The regular congregation of various avian species along stopover sites provides ample opportunities for virus transmission between different taxonomic groups, which is reinforced by molecular evidence of interspecies spillover events. Such patterns mirror the dynamics observed in other serotypes where minor variations in host susceptibility and environmental persistence manifest as transient or endemic infections in wild avian communities [2, 5].

Interspecies Transmission between Wild and Domestic Populations

The interface between wild birds and domestic poultry represents a critical nexus for the transmission dynamics of APMVs. Free-ranging domestic birds often share overlapping habitats with wild migratory species, which facilitates the introduction of novel viral strains into poultry populations. Although APMV-9 has not been as widely implicated in severe disease outbreaks as its APMV-1 counterpart, experimental studies indicate that the seroconversion profile and immune responses in chickens following APMV-9 infection differ notably from those elicited by other serotypes [2, 4]. This disparity not only reflects the unique antigenic properties of APMV-9 but also suggests that subclinical infections could contribute to viral maintenance in poultry, potentially complicating vaccination and control strategies. In countries where the poultry industry is heavily integrated with backyard production systems, wild-to-domestic transmission dynamics have been identified as significant drivers of viral spread and evolution [8, 9]. Control efforts recommended by governmental agencies such as the U.S. Centers for Disease Control and Prevention (CDC) and international bodies like the FAO emphasize rigorous surveillance at these interfaces to preempt outbreaks of economically critical diseases.

Biological Mechanisms and Viral Evolution

At the molecular level, the epidemiologic behavior of APMV-9 is governed by factors such as viral replication efficiency, host immune pressure, and the dynamics of virus–host adaptation. Studies examining the replication kinetics and pathogenicity of various APMV serotypes in both cell culture and avian hosts have shown that differences in the fusion (F) and hemagglutinin-neuraminidase (HN) proteins play a significant role in dictating tissue tropism, shedding patterns, and ultimately, the efficiency of transmission [2, 4]. The cleavage site of the F protein, an essential determinant of virulence in APMV-1, is similarly implicated in the pathobiology of other serotypes, though APMV-9 appears to induce only limited systemic spread in experimental chicken models [2]. Nonetheless, even low-pathogenic serotypes can undergo genetic evolution through point mutations and recombination events, a process that is accentuated by the high replication rates observed during interspecies transmission events and in environments where birds are densely congregated [10]. The resulting genetic diversity may enable APMV-9 to adapt to new hosts or ecological niches, complicating efforts to design effective vaccines and diagnostic assays, as even minor genomic shifts can impact viral antigenicity and immune recognition.

Environmental and Ecological Drivers

Environmental factors, including temperature, humidity, and the density of bird populations, profoundly impact the epidemiology of APMVs. Dense aggregations of birds during migration or at communal roosting sites present ideal conditions for viral amplification and sustained transmission cycles. Studies conducted in regions with high migratory bird traffic have shown that even viruses characterized by low virulence in captive studies can attain significant prevalence in the field [6, 11]. In these settings, multiple serotypes can co-circulate, occasionally leading to co-infections that may result in reassortment or recombination events. Such interactions, detected through advanced molecular surveillance techniques, underscore the importance of continuous monitoring and genetic characterization of circulating viral strains. When viral exchange occurs between domestic poultry and wild species along shared habitats, often at live bird markets or backyard farms, there is an increased risk of immunologically novel viruses emerging that could impact both animal and public health [8, 9]. The epidemiologic patterns observed in APMV-9, while distinct in some respects, are therefore symptomatic of broader ecological trends affecting avian pathogens worldwide.

Implications for Surveillance and Control

Given the potential for APMV-9 to circulate silently and alter the immune landscape of avian populations, robust surveillance that integrates molecular, serological, and ecological data is essential. Programs implemented by national veterinary services, guided by recommendations from the World Organisation for Animal Health (WOAH) and monitored by the FAO, play a pivotal role in early detection and the assessment of transmission hotspots [8, 9]. These initiatives often involve the sampling of a broad range of avian species, with subsequent genetic analyses revealing inter-taxa transmission events and region-specific viral clustering. The detection of even low-pathogenic serotypes such as APMV-9 in wild birds can act as an early warning signal, allowing for targeted interventions in domestic flocks before widespread outbreaks occur. In this context, understanding the epidemiology and transmission dynamics of APMV-9 is not only relevant for maintaining the health of wild bird populations but also crucial for safeguarding global poultry industries and ensuring food security, especially in regions where poultry serves as a critical protein source.

Collectively, the available research underscores that while APMV-9 may not currently represent the highest risk among avian paramyxoviruses, its epidemiologic behavior is intricately linked with that of other emerging and evolving avian pathogens. Continuous and comprehensive monitoring of its spread in both wild and domestic populations remains essential in order to preempt potential shifts in virulence or transmission patterns that could have significant economic and public health repercussions.

Diagnostic Approaches and Molecular Detection Strategies for Avian Paramyxovirus 9

The reliable detection and accurate differentiation of avian paramyxoviruses, including serotype 9 (APMV-9), is critical from both animal health and production standpoints. Given the economic impact on poultry industries worldwide and the potential for cross-species transmission acknowledged by international agencies such as the Centers for Disease Control (CDC), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH), modern diagnostic strategies are being continuously refined. In the context of APMV-9, accurate molecular identification and serological discrimination require an integrated approach, combining virological, immunological, and nucleic acid–based methods.

Molecular Detection Strategies

For the molecular detection of APMV-9, reverse transcription polymerase chain reaction (RT-PCR) techniques have become the cornerstone methodology. Samples, usually comprising cloacal and oropharyngeal swabs or tissue homogenates from infected birds, are first subjected to RNA extraction using protocols that ensure high yields of intact viral genomic material. Given the single‐stranded, negative-sense RNA genome shared among avulaviruses, including APMV-9, a high-quality RNA preparation is essential for further amplification.

Once extracted, complementary DNA (cDNA) is generated through reverse transcription. The subsequent amplification step is typically designed to target conserved regions within genes such as the matrix (M) and nucleoprotein (NP) genes. However, in differentiating APMV-9 from other serotypes, it is especially informative to focus on variable regions such as those within the fusion (F) and hemagglutinin-neuraminidase (HN) genes. The cleavage site within the F protein, which is known to be critical in virulence determination for several avian paramyxoviruses, offers a valuable molecular marker for serotype differentiation and epidemiological studies [4, 12]. In many laboratories, nested RT-PCR protocols or real-time RT-PCR assays are employed to increase sensitivity and specificity, allowing detection even when viral loads are low.

High-throughput next-generation sequencing (NGS) platforms have also been increasingly integrated into diagnostic pipelines. NGS not only confirms the presence of APMV RNA but also provides complete genomic information that is essential for determining evolutionary relationships among isolates. For instance, the application of simplified deep sequencing methods has revealed evidence of recombination events and inter-lineage diversifications in avian paramyxoviruses [10]. Although these studies have often focused on major serotypes like APMV-1 or NDV, the same technological approaches are directly adaptable to APMV-9. Such comprehensive sequence data are invaluable for outbreak investigations, helping to determine whether an emergent strain represents a novel introduction or a local evolution within a particular geographic region.

Multiplex real-time RT-PCR assays have been designed to simultaneously screen for several avian paramyxovirus serotypes in field samples, thereby providing a cost-effective and rapid diagnostic tool. In the context of wild bird surveillance and commercial poultry monitoring, such assays are particularly beneficial where coinfection with influenza A viruses or other paramyxovirus serotypes has been reported [5]. The design of primer-probe sets that specifically bind to unique segments of the APMV-9 genome minimizes cross-reactivity with closely related serotypes, thereby reducing false-positive rates. These strategies are further enhanced by the use of internal controls that validate both the extraction process and the amplification reaction.

In addition to conventional RT-PCR and NGS, loop-mediated isothermal amplification (LAMP) assays represent an emerging diagnostic modality that can be performed in lower-resource settings while still maintaining high sensitivity. Although specific LAMP assays for APMV-9 are still in developmental phases, their successful application to other APMV serotypes suggests that similar assays could be adapted to rapidly screen at the point of care, particularly during live bird market surveillance or outbreak investigations [4, 12].

Serological and Recombinant Antigen-Based Diagnostics

Complementary to nucleic acid–based diagnostics, serology plays a pivotal role in determining the exposure history and immune status within poultry populations. Enzyme-linked immunosorbent assays (ELISAs) have been optimized using recombinant proteins expressed in bacterial systems. For example, the full-length nucleoprotein (NP) or its C-terminal fragments have been used with varying success; while full-length NP offers high sensitivity, truncated regions can enhance specificity by reducing cross-reactivity with antibodies generated against other avian paramyxovirus serotypes [13]. Although many serological assays have been tailored primarily for Newcastle disease virus (APMV-1), the strategies are readily adapted for APMV-9 by using expressed proteins from the homologous viral strain. This method is particularly useful in endemic areas where multiple APMV serotypes may be co-circulating and where serological cross-reactivity may otherwise confound diagnosis.

Advances in immunofluorescence assays (IFA) and virus neutralization tests (VNT) further contribute to the diagnostic repertoire. In these assays, monoclonal antibodies specific to epitopes unique to APMV-9 are used to differentiate it from other serotypes. Although isolating such monoclonal antibodies requires extensive antigen screening, their production remains a critical step in developing a serotype-specific rapid diagnostic test. These assays are especially important for confirming RT-PCR results and for epidemiological studies that trace serotype-specific exposure in both wild and domestic avian populations.

Integration of Molecular and Serological Diagnostics in Surveillance Programs

International agencies such as the FAO advocate for integrated surveillance strategies that combine both molecular detection and serological profiling. The deployment of such combined diagnostic strategies provides a comprehensive view of the infection landscape, aids in early detection, and informs vaccination strategies. In countries with intensive poultry production, where vaccination programs are monitored by regulatory bodies, such as the CDC and OIE, diagnostic protocols have traditionally focused on APMV-1. However, emerging evidence underscores the need for parallel surveillance of other avian paramyxovirus serotypes, including APMV-9. This is particularly important in situations where co-infections are common, and where subtle genetic variances can alter viral behavior, replication efficiency, or immune evasion capabilities [3, 2].

Field laboratories often employ a two-step approach: initial broad-spectrum RT-PCR assays screen for the presence of any avian paramyxovirus, followed by serotype-specific assays that identify APMV-9 through sequencing of the key genomic regions. The implementation of such diagnostic workflows minimizes misclassification and allows rapid epidemiological assessments following suspected outbreaks in poultry farms or live bird markets. The continuous evolution of these viruses mandates regular updates to primer and probe design based on the latest sequence data, ensuring that diagnostic tests remain accurate and robust in the face of genetic drift and recombination events [10].

In summary, the diagnostic approaches for APMV-9 encompass a meticulously coordinated application of molecular detection tools, from sensitive, multiplex RT-PCR assays to cutting-edge next-generation sequencing methods, coupled with serological techniques that leverage recombinant antigen technology for specificity. These methods, endorsed by international regulatory agencies, are essential for timely and accurate detection, thereby supporting robust disease surveillance and control measures in both commercial poultry and wild bird populations.

Genomic Diversity, Evolutionary Trends, and Host Adaptation

Avian paramyxoviruses (APMVs) form a diverse group of enveloped, single-stranded negative-sense RNA viruses that include at least nine recognized serotypes. Although much of the historical focus has been placed on APMV-1 (Newcastle disease virus) due to its devastating impact on poultry, the genomic architecture and evolutionary trajectory of other serotypes, such as APMV-9, are gradually emerging as key subjects in understanding viral evolution and interspecies transmission in wild and domestic birds [1-3].

Genomic Architecture and Inherent Diversity

A defining feature common to all APMVs is the canonical gene order: 3′-N-P-M-F-HN-L-5′. In APMV-9, as in its fellow members, the nucleocapsid (N), phosphoprotein (P), matrix (M), fusion (F), hemagglutinin-neuraminidase (HN), and large polymerase (L) genes are arranged in this conserved sequence. Comparative genomic studies highlight that while the overall organization remains structurally conserved across serotypes, the evolutionarily dynamic regions are concentrated primarily within the F and HN genes. These gene products are directly implicated in host cell receptor binding and membrane fusion, functions that are crucial for viral entry and subsequent spread between cells. The accumulation of subtle nucleotide changes, primarily nonsynonymous substitutions, is a hallmark of adaptive evolution driven by host immune pressures, and APMV-9 is no exception [3, 2].

Whole-genome sequencing efforts, albeit more extensive for other serotypes, have enabled researchers to delineate the conserved and variable domains within these viruses. In APMV-9, there is evidence of low to moderate levels of genetic divergence compared to other naturally circulating APMV serotypes. This moderate genomic variability is indicative of the virus’s adaptation to a broad range of avian hosts while maintaining key functions required for replication and transmission. The preservation of the canonical gene order across APMVs points to strong purifying selection pressure in maintaining viral fitness, even as minor gene-specific mutations accumulate in regions that are in direct contact with the host immune system [3, 2].

Evolutionary Trends and Molecular Mechanisms

The evolutionary trends observed in APMVs, including APMV-9, can be attributed to a balance between genomic plasticity and functional constraints. The fusion (F) protein cleavage site often serves as a molecular marker for virulence in NDV and has been extensively studied; however, in case of APMV-9, the cleavage site typically exhibits characteristics consistent with an avirulent phenotype in domestic poultry [2, 4]. Although modifications in the cleavage site have been shown in other serotypes to alter fusion efficiency and syncytium formation in vitro [14], APMV-9’s evolutionary strategy appears to favor replication efficiency and host adaptability over high virulence. This delicate interplay suggests that APMV-9 maintains sufficient replication competence within diverse host species without triggering the severe pathological consequences observed with highly virulent strains of APMV-1.

Evolutionary reconstruction using methods such as Bayesian inference has revealed that APMVs overall diverge at rates which reflect significant evolutionary constraints yet also allow for periodic adaptive shifts. While recombination events in negative-sense RNA viruses are rare, reports of inter-lineage natural recombination have occasionally surfaced among APMVs [10]. For APMV-9, current genomic analyses suggest that natural recombination is not a prominent feature, and the evolutionary trajectory appears to be shaped more by point mutations under purifying and, occasionally, positive selection pressures. Such selective pressures are driven by host immune responses, particularly targeting the surface glycoproteins. In APMV-9, the HN protein, which mediates receptor binding, is likely under similar pressures, leading to antigenic drift that aids in immune evasion and promotes persistent low-level circulation in host populations [3, 2].

Host Adaptation and Ecological Dynamics

Host adaptation in avian paramyxoviruses is a multifactorial process, and APMV-9 illustrates how a virus can achieve an optimal balance between effective replication and evasion of host immune defenses. In natural ecosystems, APMV-9 has been detected in both wild birds and domestic poultry, where it generally exhibits an avirulent profile. Such subclinical infections are a common theme among many APMV serotypes and confer an advantage for the virus, allowing it to persist in host populations without provoking significant host mortality, which might otherwise limit viral spread.

The ability of APMV-9 to infect a wide range of avian hosts suggests that it has evolved mechanisms to adapt to diverse cellular environments. This versatility is likely driven by the genomic factors outlined above, particularly the fine-tuning of the F and HN proteins, which not only determine cellular tropism but also modulate host immune recognition. Field studies have shown that while immunization with APMV-9 in chickens produces measurable immune responses, manifested as partial protection against challenge with virulent NDV, these responses may be less robust than those elicited by other serotypes, such as APMV-3 [2]. This disparity possibly reflects differential host adaptation, with APMV-9 evolving under selection pressures that favor an avirulent, endemic state over acute pathogenicity.

Environmental and ecological factors further modulate the evolutionary trajectory of APMV-9. Migratory birds, which are known reservoirs for various APMVs, often serve as vehicles for long-range dispersal and interspecies transmission. The congregation of diverse species at migratory stopover points fosters opportunities for viral exchange and genetic diversification. Although data is more robust for some serotypes in demonstrating these patterns, documented by global surveillance efforts recognized by the World Health Organization (WHO) and the World Organisation for Animal Health (WOAH), the same evolutionary dynamics likely apply to APMV-9 [15, 16]. The overlap of migratory flyways with areas of high poultry density underscores the necessity for ongoing genome-based surveillance programs, as urged by international agencies such as the CDC and FAO, to preempt potential zoonotic or economically disruptive outbreaks.

In addition, the subclinical nature of APMV-9 in domestic poultry allows it to circulate stealthily, thereby serving as a reservoir for genetic variability that may eventually give rise to emergent variants. The differential replication of APMV-9 observed in various avian species highlights the complex interplay between viral adaptation and host intrinsic factors such as immune status and cellular receptor distribution. Even subtle amino acid substitutions in key glycoproteins might alter tissue tropism or modulate the immune response, further illustrating the evolutionary finesse that characterizes this virus [3, 2].

Comparative studies of APMV serotypes have consistently shown that host adaptation is not merely a consequence of random mutation but rather a directed process influenced by the environmental pressures encountered by the virus. For APMV-9, maintaining a relatively stable but adaptable genome likely confers an evolutionary benefit that facilitates transmission across a wide spectrum of avian hosts without inciting the overt disease that would prompt immediate control measures. Such adaptation strategies render it a virus of considerable interest not only from an academic perspective but also for veterinary public health, as underscored by organizations like the CDC, WHO, and FAO.

Immune Response Dynamics in Avian Paramyxovirus 9 Infection

Avian paramyxovirus serotype 9 (APMV-9) exhibits unique host interaction patterns that drive both innate and adaptive immune responses in avian systems. Although APMV-9 is relatively less studied compared to its serotype-1 cousin (Newcastle disease virus [NDV]), research into other APMV serotypes offers valuable insights into its immunological profile. Like other avulaviruses, upon infection, APMV-9 initiates host pathogen recognition receptor (PRR) activation, notably through RIG-I and toll-like receptors. These molecular interactions trigger a cascade of interferon production and the recruitment of innate immune cells, setting the stage for a robust antiviral state. The subsequent antigen presentation via dendritic cells and lymphoid tissues stimulates both humoral and cell-mediated adaptive immunity, leading to the production of virus-specific IgG and local secretory IgA, components essential for controlling viral replication in mucosal tissues such as the respiratory tract [17, 18].

Vaccine Development Strategies Using APMV Vectors

Both the natural immunogenicity and the amenability to genetic manipulation position avian paramyxoviruses as promising platforms for vaccine development. Although the majority of detailed vaccine studies have concentrated on serotype-1 (NDV) or serotype-3, emerging research has evaluated serotypes 2–9 in terms of their capacity to induce protective immunity. In one extensive study, chickens immunized with various APMV serotypes demonstrated differential levels of cross-protection against a virulent NDV challenge. Notably, immunization with APMV-9 yielded a survival rate of approximately 52.5% and contributed to a reduction in NDV replication in the brain, although this protective immunity was not as robust as that elicited by APMV-3 [2]. This partial protection underscores the significance of both humoral responses and local viral replication restriction in the development of effective vaccines. It also highlights the need for fine-tuning vaccine candidates based on antigen composition and vector selection to overcome the limitations of pre-existing immunity that can interfere with conventional NDV vaccination programs [19, 20].

Recombinant avian paramyxoviruses have been designed through reverse genetics to express foreign immunogens, thereby expanding the utility of these viruses as vaccine vectors. For instance, recombinant strategies using APMV-3 have demonstrated high-level foreign gene expression and potent mucosal and systemic immune responses following intranasal administration [18, 21]. These same approaches could be adapted to APMV-9, using targeted mutations or gene insertions, to optimize antigen presentation while maintaining a safe and attenuated phenotype. The ultimate goal is to create a vector that not only induces broadly neutralizing antibodies but also effectively stimulates cytotoxic T lymphocyte responses that are critical for viral clearance [2, 22]. The non-pathogenic nature of several APMV serotypes, as evidenced by the limited clinical manifestations even in the presence of vigorous replication in selected tissues [4], further solidifies the case for their role in vaccine design.

Therapeutic Strategies and Oncolytic Applications

Beyond traditional vaccination, avian paramyxoviruses have been explored for their oncolytic properties and potential in immunotherapy. Although APMV-9 is primarily considered in the realm of vaccination studies, investigations into other serotypes, such as APMV-4, have shown that certain avulaviruses can elicit potent antitumor responses in preclinical tumor models [23, 24]. These observations open avenues for the therapeutic use of APMV-9 in modulating the immune system. By promoting a localized cytokine milieu and enhancing infiltration by immune effector cells such as CD8+ T lymphocytes, genetically engineered paramyxoviruses could serve dual functions, acting as vaccines and, concurrently, as oncolytic agents. The mechanistic basis of these effects appears rooted in the virus’s ability to induce a strong interferon response and to upregulate the expression of immunomodulatory molecules that enhance tumor antigen presentation [23].

Strategies for therapeutic intervention involving APMV-9 could integrate its inherent immune-stimulating properties with transgene expression. For instance, by encoding foreign antigens or immune-stimulatory cytokines, recombinant APMV vectors can be tailored to enhance the immunogenicity of co-administered antigens, a strategy that has already proven effective with APMV-3 constructs in preclinical models for respiratory viruses and even Ebola virus [18, 25]. Given guidelines from international agencies such as the World Organisation for Animal Health (WOAH) and recommendations by the Centers for Disease Control (CDC) regarding zoonotic and economically significant avian pathogens, any therapeutic strategy must consider robust safety profiles, the potential for viral reversion, and the ability to induce both systemic and mucosal immunity. This is particularly critical in regions with intensive poultry production where the economic impact of avian diseases is pronounced [9, 19].

Immunological Mechanisms Informing Vaccine Design

The detailed evaluation of immune responses elicited by avian paramyxoviruses has provided profound biological insights that inform the rational design of vaccines and immunotherapeutic agents. Upon infection, the activation of innate immune sensors leads to the production of interferon-stimulated genes (ISGs) and a local inflammatory response that recruits both innate and adaptive immune cells. The interplay between these immune compartments is reflected in the expansion of CD4+, CD8+, and B cells in key lymphoid tissues such as the Harderian gland, as observed in studies with wild-bird-origin isolates [17]. Such local immune responses not only contribute to the clearance of the virus but also promote the establishment of immunological memory, a feature that is essential for long-term vaccine efficacy.

Furthermore, the role of mucosal immunity cannot be overstated; the induction of secretory IgA, particularly in the upper respiratory tract, serves as a critical barrier to infection and viral shedding. Live attenuated vaccines based on avian paramyxoviruses, administered via the intranasal route, have proven capable of effectively stimulating both mucosal and systemic immune responses, with protective outcomes observed in multiple animal models [18, 20]. These findings lay the groundwork for the potential harnessing of APMV-9 as an effective vaccine vector that could offer a balance between immunogenicity and safety. Advances in reverse genetic techniques allow for precise modifications to the viral genome, enabling vaccine developers to manipulate antigen expression levels, tissue tropism, and replication efficiency to maximize immunoprotective effects while minimizing adverse responses [2, 26, 21].

Leveraging these immunological insights is central to counteracting emerging and endemic avian pathogens, and the integration of APMV-based strategies aligns with global efforts led by organizations such as the CDC and WHO to manage avian diseases that carry significant zoonotic potential and economic repercussions.

Future Directions and Control Measures for Avian Paramyxovirus 9

Avian Paramyxovirus serotype 9 (APMV-9) represents one of the less prominent yet increasingly significant members of the avulavirus group. Despite its relatively low profile compared to the highly pathogenic APMV-1 (Newcastle disease virus), APMV-9 has garnered attention due to its potential impact on poultry health and its role in shaping the broader ecology of avian viruses. Future research must delve into its molecular biology, immunogenic properties, and transmission dynamics to facilitate the design of robust control measures. In this regard, multi-disciplinary efforts integrating molecular virology, epidemiology, and immunology, with guidance from authoritative agencies such as the World Organisation for Animal Health (WOAH), the World Health Organization (WHO), and the Centers for Disease Control and Prevention (CDC), are essential.

Molecular Characterization and Evolutionary Studies

One key research direction is an in-depth molecular characterization of APMV-9. Recent experimental evaluations in non-human primate models have demonstrated that while APMV-9 is capable of infecting hosts, its replication remains moderately restricted compared to other serotypes [3]. Future studies should employ advanced reverse genetics systems and next-generation sequencing methodologies to map the genome-wide determinants of viral replication, tissue tropism, and host immune evasion strategies. This detailed molecular analysis is expected to uncover specific genetic markers that could facilitate differentiation between vaccine strains and field isolates, a principle central to DIVA (Differentiating Infected from Vaccinated Animals) strategies, as discussed in the context of other paramyxoviruses [13]. Understanding the phylogenetic relationships and mutation rates among APMV-9 isolates will also inform on interspecies transmission events and the role of migratory birds in seeding viral diversity.

Moreover, characterizing the structure–function relationship of key structural proteins, such as the fusion (F) protein and the hemagglutinin–neuraminidase (HN) glycoprotein, is crucial. Although extensive studies have been carried out on the fusion mechanisms in other APMV serotypes, similar investigations in APMV-9 could illuminate unique features that influence its immunogenicity and virulence. These findings may serve as a basis for tailoring recombinant vaccine vectors that express antigenic determinants of APMV-9 or even chimeric constructs to induce broad-spectrum immunity.

Immunogenicity and Vaccine Potential

Control measures for APMV-9 hinge significantly on a comprehensive understanding of its immunogenic profile. In experimental settings, immunization of chickens with APMV serotypes, including APMV-9, has shown partial protection against challenge with virulent Newcastle disease virus, with APMV-9-immunized birds achieving around 52.5% survival after subsequent challenge [2]. Such results indicate that while there is inherent cross-reactivity, APMV-9 may serve as both an indirect mediator of cross-protection and as a potential vaccine vector platform. Future research must optimize the dosage, administration route, and formulation of APMV-9 vaccines in order to enhance the magnitude and breadth of the immune response in target species.

In addition, exploration of alternative vaccine platforms, such as live attenuated viruses and vectored vaccines, can address the limitations of inactivated or conventional vaccines currently deployed against economically critical avian diseases. Several studies have demonstrated that modifying the F protein cleavage site can influence viral replication in vitro and host immune activation, without necessarily increasing virulence in vivo [14]; similar approaches might be applied to APMV-9 to boost its immunogenicity while maintaining an avirulent profile suitable for vaccination. Comparative studies across different APMV serotypes will further refine which genetic and antigenic configurations yield optimal immunoprotection.

Surveillance, Epidemiology, and Diagnostic Enhancements

Given that APMV-9 has been shown to replicate in various hosts with moderately efficient infection rates, prolonged surveillance in both wild and domestic avian populations is crucial. Epidemiological studies should focus on mapping the geographical distribution and temporal dynamics of APMV-9. Integrating molecular surveillance with traditional field sampling in major migratory routes, as recommended by global organizations like the FAO, can provide critical insights into virus transmission patterns. This is especially important as migratory birds may act as reservoirs and vectors, thereby influencing local and intercontinental virus spread [3].

Additionally, the development and refinement of molecular diagnostic assays must remain a research priority. The specificity of real-time reverse transcription PCR (rRT-PCR) assays for APMV-9, leveraging unique genomic sequences, is vital to rapidly differentiate between virulent and avirulent strains and to implement early warning systems in accordance with WHO and WOAH guidelines. Novel serological assays that minimize cross-reactivity with other paramyxoviruses should also be pursued, thereby ensuring that diagnostic tools accurately reflect the prevalence of APMV-9 in mixed infection scenarios.

Biosecurity and Field Control Measures

Beyond laboratory studies, field-level control measures must evolve in parallel. Poultry production systems, particularly in developing countries, are vulnerable to outbreaks triggered by mixed infections. Comprehensive biosecurity practices, including strict disinfection protocols, controlled access to poultry facilities, and routine monitoring for viral pathogens, are foundational to mitigating outbreaks associated with APMV-9. Educational initiatives aimed at both commercial and backyard poultry farmers should emphasize the importance of early detection and adherence to vaccination schedules.

Furthermore, government agencies such as the CDC, WHO, and WOAH stress the need for coordinated response mechanisms during viral outbreaks. The implementation of a regional and global surveillance network that incorporates rapid sharing of genomic data and epidemiological findings will immensely contribute to steering timely interventions and adapting vaccination programs. Adoption of a One Health approach, which considers the interconnectedness of human, animal, and environmental health, could be instrumental in curbing the potential economic and zoonotic risks posed by APMV-9, even if its zoonotic potential is currently considered low [3, 12].

Integration of Advanced Technologies and Collaborative Research

Finally, integration of modern technologies, such as high-throughput sequencing, bioinformatics for phylodynamic analyses, and systems biology approaches, will enable researchers to detect subtle shifts in viral genetics and predict emerging strains. These approaches are pivotal for tailoring vaccines that can keep pace with the evolutionary dynamics of APMV-9. Collaborative networks involving academic institutions, government bodies, and international organizations will be essential in harnessing these technologies effectively, thereby strengthening control measures at local, regional, and global scales.

By advancing molecular studies, optimizing immunogenicity, enhancing surveillance, and rigorously implementing biosecurity protocols, the veterinary research community can position itself to manage and control Avian Paramyxovirus 9 effectively, thereby safeguarding poultry health and mitigating economic losses at a global level.

References

[1] Gogoi P, Ganar K, Kumar S. Avian Paramyxovirus: A Brief Review. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12355

[2] Nayak B, Dias F, Kumar S, Paldurai A, Collins P, Samal S. Avian paramyxovirus serotypes 2-9 (APMV -2-9) vary in the ability to induce protective immunity in chickens against challenge with virulent Newcastle disease virus (APMV-1). Vaccine. 2012. DOI: https://doi.org/10.1016/j.vaccine.2011.12.090

[3] Khattar S, Nayak B, Kim S, Xiao S, Samal S, Paldurai A, et al.. Evaluation of the Replication, Pathogenicity, and Immunogenicity of Avian Paramyxovirus (APMV) Serotypes 2, 3, 4, 5, 7, and 9 in Rhesus Macaques. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0075456

[4] Kim S, Xiao S, Shive H, Collins P, Samal S. Replication, Neurotropism, and Pathogenicity of Avian Paramyxovirus Serotypes 1–9 in Chickens and Ducks. PLoS ONE. 2012. DOI: https://doi.org/10.1371/journal.pone.0034927

[5] Wille M, Avril A, Tolf C, Schager AE, Larsson S, Borg O, et al.. Temporal dynamics, diversity, and interplay in three components of the virodiversity of a Mallard population: Influenza A virus, avian paramyxovirus and avian coronavirus. Infection, Genetics and Evolution. 2014. DOI: https://doi.org/10.1016/j.meegid.2014.11.014

[6] Tolf C, Wille M, Haidar A, Avril A, Zohari S, Waldenström J. Prevalence of avian paramyxovirus type 1 in Mallards during autumn migration in the western Baltic Sea region. Virology Journal. 2013. DOI: https://doi.org/10.1186/1743-422X-10-285

[7] Reeves AB, Poulson R, Muzyka D, Ogawa H, Imai K, Bui VN, et al.. Limited evidence of intercontinental dispersal of avian paramyxovirus serotype 4 by migratory birds. Infection, Genetics and Evolution. 2016. DOI: https://doi.org/10.1016/j.meegid.2016.02.031

[8] Shabbir M, Mahmood S, ul-Rahman A, Banyard A, Ross CS. Genomic Diversity and Evolutionary Insights of Avian Paramyxovirus-1 in Avian Populations in Pakistan. Viruses. 2024. DOI: https://doi.org/10.3390/v16091414

[9] Mansour S, ElBakrey RM, Mohamed FF, Hamouda EE, Abdallah M, Elbestawy A, et al.. Avian Paramyxovirus Type 1 in Egypt: Epidemiology, Evolutionary Perspective, and Vaccine Approach. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.647462

[10] Satharasinghe D, Murulitharan K, Tan SW, Yeap S, Munir M, Ideris A, et al.. Detection of Inter-Lineage Natural Recombination in Avian Paramyxovirus Serotype 1 Using Simplified Deep Sequencing Platform. Frontiers in Microbiology. 2016. DOI: https://doi.org/10.3389/fmicb.2016.01907

[11] Umali D, Ito H, Katoh H, Ito T. Surveillance of Avian Paramyxovirus in Migratory Waterfowls in the San-in Region of Western Japan from 2006 to 2012. Journal of Veterinary Medical Science. 2013. DOI: https://doi.org/10.1292/jvms.13-0539

[12] Hines N, Miller CL. Avian Paramyxovirus Serotype-1: A Review of Disease Distribution, Clinical Symptoms, and Laboratory Diagnostics. Veterinary Medicine International. 2012. DOI: https://doi.org/10.1155/2012/708216

[13] Zhao N, Grund C, Beer M, Harder T. Engineered recombinant protein products of the avian paramyxovirus type-1 nucleocapsid and phosphoprotein genes for serological diagnosis. Virology Journal. 2018. DOI: https://doi.org/10.1186/s12985-018-0924-8

[14] Kim S, Xiao S, Shive H, Collins P, Samal S. Mutations in the Fusion Protein Cleavage Site of Avian Paramyxovirus Serotype 4 Confer Increased Replication and Syncytium Formation In Vitro but Not Increased Replication and Pathogenicity in Chickens and Ducks. PLoS ONE. 2013. DOI: https://doi.org/10.1371/journal.pone.0050598

[15] Hicks J, Dimitrov K, Afonso C, Ramey A, Bahl J. Global phylodynamic analysis of avian paramyxovirus-1 provides evidence of inter-host transmission and intercontinental spatial diffusion. BMC Evolutionary Biology. 2019. DOI: https://doi.org/10.1186/s12862-019-1431-2

[16] Ramey A, Goraichuk I, Hicks J, Dimitrov K, Poulson R, Stallknecht D, et al.. Assessment of contemporary genetic diversity and inter-taxa/inter-region exchange of avian paramyxovirus serotype 1 in wild birds sampled in North America. Virology Journal. 2017. DOI: https://doi.org/10.1186/s12985-017-0714-8

[17] Espejo R, Toro H. Mucosal immune responses elicited by wild-bird-origin avian paramyxovirus-type 1 isolates in chickens.. Avian Pathology. 2026. DOI: https://doi.org/10.1080/03079457.2026.2630676

[18] Park H, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X, et al.. Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. npj Vaccines. 2022. DOI: https://doi.org/10.1038/s41541-022-00493-x

[19] Ross CS, Mahmood S, Skinner P, Mayers J, Reid S, Hansen RDE, et al.. JMM Profile: Avian paramyxovirus type-1 and Newcastle disease: a highly infectious vaccine-preventable viral disease of poultry with low zoonotic potential.. Journal of Medical Microbiology. 2022. DOI: https://doi.org/10.1099/jmm.0.001489

[20] Yang W, Dai J, Liu J, Guo M, Liu X, Hu S, et al.. Intranasal Immunization with a Recombinant Avian Paramyxovirus Serotypes 2 Vector-Based Vaccine Induces Protection against H9N2 Avian Influenza in Chicken. Viruses. 2022. DOI: https://doi.org/10.3390/v14050918

[21] Yoshida A, Samal S. Avian Paramyxovirus Type-3 as a Vaccine Vector: Identification of a Genome Location for High Level Expression of a Foreign Gene. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.00693

[22] Soliman RM, Nishioka K, Murakoshi F, Nakaya T. Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein. Veterinary Research. 2024. DOI: https://doi.org/10.1186/s13567-024-01271-4

[23] Bykov Y, Javaheri A, Mena I, García‐Sastre A, Cuadrado-Castano S. Avian paramyxovirus 4 has potent antitumor activity that surpasses the oncolytic effect of NDV in colon carcinoma and melanoma in vivo models. Journal of Immunology. 2023. DOI: https://doi.org/10.4049/jimmunol.210.supp.245.20

[24] Javaheri A, Bykov Y, Mena I, García‐Sastre A, Cuadrado-Castano S. Avian Paramyxovirus 4 Antitumor Activity Leads to Complete Remissions and Long-term Protective Memory in Preclinical Melanoma and Colon Carcinoma Models. Cancer Research Communications. 2022. DOI: https://doi.org/10.1158/2767-9764.crc-22-0025

[25] Yoshida A, Kim S, Manoharan VK, Varghese BP, Paldurai A, Samal S. Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-42004-4

[26] Elbehairy MA, Khattar S, Samal S. Recovery of Recombinant Avian Paramyxovirus Type-3 Strain Wisconsin by Reverse Genetics and Its Evaluation as a Vaccine Vector for Chickens. Viruses. 2021. DOI: https://doi.org/10.3390/v13020316